EUVIMEDEUVIMED entdecken
Crossref

Intensive salvage chemotherapy with VDTPACE or mCBAD followed by hematopoietic stem‐cell support for refractory/relapsed multiple myeloma

Carolina Perrone Marques, Danielle Ovigli, Mariana Nassif Kerbauy iD, Ana Carolina de Almeida Silveira, Ricardo Helman, Cinthya Correa da Silva, Andreza Alice Feitosa Ribeiro, Nelson Hamerschlak iD, Leonardo Javier Arcuri iD

European Journal of Haematology · 2024

DOI: 10.1111/ejh.14257 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Carolina Perrone Marques und 8 weiteren Autor:innen. Beteiligte Einrichtung: Bone Marrow Transplant Department, Hospital Israelita Albert Einstein, São Paulo, Brazil. Hauptthemen laut MEDLINE: Multiple Myeloma, Salvage Therapy, Hematopoietic Stem Cell Transplantation, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 23 Literaturangaben. Gefördert von: AMGEN.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Triple‐ and quad‐refractory multiple myeloma patients usually have an aggressive course and a poor prognosis. Available therapeutic options are scarce.

Methods

The objective of the current study was to evaluate responses and toxicities of VDTPACE or mCBAD with hematopoietic stem‐cell support as a bridge to subsequent therapies in patients with refractory/relapsed multiple myeloma.

Results

Thirteen patients were included (11 mCBAD, 2 VDTPACE), and 21 cycles of chemotherapy with hematopoietic stem‐cell support were delivered. Mean number of previous therapies was 4.8. Stem cells were infused on a median day 9.9 after chemotherapy. Mean time to neutrophil recovery was 18.2 days in patients receiving the first cycle and 15.9 following subsequent cycles. Before therapy, most patients were in PD (77%), PR (15%), or VGPR (8%). Following treatment, the best responses achieved were PR (46%), VGPR (46%), and CR (8%). Median overall and progression‐free survivals were 17 and 9 months. There has been no case of non‐relapse mortality. In the 21 cycles, the main complications were infectious.

Conclusion

Intensive chemotherapy can decrease disease burden in patients with relapsed/refractory MM, and stem‐cell support can successfully decrease toxicities and treatment‐related mortality associated with these regimens and may be a good bridging option.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaSalvage TherapyHematopoietic Stem Cell TransplantationAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedAgedTreatment OutcomeDrug Resistance, NeoplasmCombined Modality TherapyRecurrenceAdult

Stichwörter der Autor:innen

bridging chemotherapyhematopoietic stem‐cell supportintensive chemotherapyrelapsed/refractory multiple myeloma

Autor:innen und Institutionen

  • Bone Marrow Transplant Department, Hospital Israelita Albert Einstein, São Paulo, Brazil.
  • Academic Research Organization, Hospital Israelita Albert Einstein, São Paulo, Brazil.

ORCID-Profile: Mariana Nassif Kerbauy, Nelson Hamerschlak, Leonardo Javier Arcuri

Förderung

  • AMGEN

Zitieren

APA

Marques, C. P., Ovigli, D., Kerbauy, M. N., Silveira, A. C. A., Helman, R., da Silva, C. C., Ribeiro, A. A. F., Hamerschlak, N., & Arcuri, L. J. (2024). Intensive salvage chemotherapy with VDTPACE or mCBAD followed by hematopoietic stem‐cell support for refractory/relapsed multiple myeloma. European Journal of Haematology. https://doi.org/10.1111/ejh.14257

Vancouver

Marques CP, Ovigli D, Kerbauy MN, Silveira ACA, Helman R, da Silva CC, et al. Intensive salvage chemotherapy with VDTPACE or mCBAD followed by hematopoietic stem‐cell support for refractory/relapsed multiple myeloma. European Journal of Haematology. 2024. doi:10.1111/ejh.14257

BibTeX
@article{Marques2024,
  author = {Marques, Carolina Perrone and Ovigli, Danielle and Kerbauy, Mariana Nassif and Silveira, Ana Carolina de Almeida and Helman, Ricardo and da Silva, Cinthya Correa and Ribeiro, Andreza Alice Feitosa and Hamerschlak, Nelson and Arcuri, Leonardo Javier},
  title = {Intensive salvage chemotherapy with VDTPACE or mCBAD followed by hematopoietic stem‐cell support for refractory/relapsed multiple myeloma},
  journal = {European Journal of Haematology},
  year = {2024},
  doi = {10.1111/ejh.14257}
}
Kostenlos starten →